Literature DB >> 11268298

Medical and surgical therapies for pain associated with endometriosis.

C A Winkel1, A R Scialli.   

Abstract

Endometriosis is a common condition for which a number of treatments have been proposed. Medical treatments are based on the hormonal responsiveness of endometriosis implants. These therapies include progestins (with or without estrogens), androgens, and gonadotropin-releasing hormone (GnRH) analogs. Surgical treatments may include hysterectomy with oophorectomy or organ-sparing surgery involving ablation or resection of visible lesions of endometriosis and restoration of pelvic anatomy. There are no studies that directly compare the effectiveness or adverse effects of medical therapy and surgical therapy. Studies on medical therapy compare different treatments with placebo or with other active treatments. Hormone-based therapies for endometriosis show 80%-100% effectiveness in relief of pelvic pain over a 6-month course of therapy. Serious adverse outcomes after medical therapy are unusual. Studies on surgical therapy are largely anecdotal, with noncomparative reports on a variety of surgical methods. A few comparative surgical studies have been reported. Because of the noncomparative nature of many of the surgical studies, the use of combinations of surgical procedures and techniques in the reported studies, and the reporting of results from surgeons with an unusually high level of technical skill, the gynecological practitioner has little basis in the literature for assessing the optimum surgical approach. Surgical complications are believed to be underreported and may be related to how aggressive a surgical procedure is undertaken.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11268298     DOI: 10.1089/152460901300039485

Source DB:  PubMed          Journal:  J Womens Health Gend Based Med        ISSN: 1524-6094


  10 in total

1.  Ultrasound-guided aspiration and ethanol sclerotherapy for treating endometrial cysts.

Authors:  G Gatta; V Parlato; G Di Grezia; A Porto; S Cappabianca; R Grassi; A Rotondo
Journal:  Radiol Med       Date:  2010-09-17       Impact factor: 3.469

2.  Medical Management of Endometriosis.

Authors:  Saima Rafique; Alan H Decherney
Journal:  Clin Obstet Gynecol       Date:  2017-09       Impact factor: 2.190

3.  Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model.

Authors:  Jaime Kulak; Catha Fischer; Barry Komm; Hugh S Taylor
Journal:  Endocrinology       Date:  2011-05-17       Impact factor: 4.736

4.  Patients' report on how endometriosis affects health, work, and daily life.

Authors:  Jessica Fourquet; Xin Gao; Diego Zavala; Juan C Orengo; Sonia Abac; Abigail Ruiz; Joaquín Laboy; Idhaliz Flores
Journal:  Fertil Steril       Date:  2010-05-01       Impact factor: 7.329

Review 5.  Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions.

Authors:  Hakan Cakmak; Hugh S Taylor
Journal:  Semin Reprod Med       Date:  2010-01-26       Impact factor: 1.303

6.  The effects of massage therapy on dysmenorrhea caused by endometriosis.

Authors:  Mahboubeh Valiani; Niloofar Ghasemi; Parvin Bahadoran; Reza Heshmat
Journal:  Iran J Nurs Midwifery Res       Date:  2010

7.  Dienogest in long-term treatment of endometriosis.

Authors:  Adolf E Schindler
Journal:  Int J Womens Health       Date:  2011-07-06

8.  Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.

Authors:  John I-Chiang Chang; Joseph Bucci
Journal:  J Med Case Rep       Date:  2016-11-11

Review 9.  Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach.

Authors:  Nadja Tariverdian; Theoharis C Theoharides; Friederike Siedentopf; Gabriela Gutiérrez; Udo Jeschke; Gabriel A Rabinovich; Sandra M Blois; Petra C Arck
Journal:  Semin Immunopathol       Date:  2007-06       Impact factor: 9.623

10.  Endometriosis of the bladder as a cause of obstructive uropathy.

Authors:  Anthony N Gyang; Nadia A Gomez; Georgine M Lamvu
Journal:  JSLS       Date:  2014 Apr-Jun       Impact factor: 2.172

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.